Monitoring Immune Responses in Neuroblastoma Patients during Therapy

Monitoring Immune Responses in Neuroblastoma Patients during Therapy

Neuroblastoma (NBL) is the most common extracranial solid tumor in childhood. Despite intense treatment, children with this high-risk disease have a poor prognosis. Immunotherapy showed a significant improvement in event-free survival in high-risk NBL patients receiving chimeric anti-GD2 in combinat...

Full description

Bibliographic Details
Main Authors:	Celina L. Szanto, Annelisa M. Cornel, Saskia V. Vijver, Stefan Nierkens
Format:	Article
Language:	English
Published:	MDPI AG 2020-02-01
Series:	Cancers
Subjects:	neuroblastoma biomarker immunotherapy anti-gd2 dinutuximab immune profiling immune monitoring adoptive cell therapy checkpoint inhibitors cytokines
Online Access:	https://www.mdpi.com/2072-6694/12/2/519

Similar Items

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
by: Aleksandra Wieczorek, et al.
Published: (2022-04-01)

A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood
by: Michelle E. Keyel, et al.
Published: (2023-09-01)

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
by: Nur Olgun, et al.
Published: (2022-12-01)

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
by: Thomas Blom, et al.
Published: (2021-02-01)

The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1
by: Adeiye A. Pilgrim, et al.
Published: (2023-12-01)

Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma
by: Celina L. Szanto, et al.
Published: (2021-04-01)

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
by: Ruth Ladenstein, et al.
Published: (2020-01-01)

GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
by: Claudia Paret, et al.
Published: (2022-12-01)

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
by: Holger N. Lode, et al.
Published: (2023-06-01)

Novel drug - dinutuximab for high-risk neuroblastoma
by: Supriya Kushwah, et al.
Published: (2018-01-01)

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model
by: Jaquelyn T. Zoine, et al.
Published: (2019-08-01)

Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
by: Godfrey Chi-Fung Chan, et al.
Published: (2022-02-01)

Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
by: Jasminka Stepan Giljević, et al.
Published: (2022-06-01)

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
by: M. Fevzi Ozkaynak, et al.
Published: (2018-07-01)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
by: Aleksandra Wieczorek, et al.
Published: (2023-02-01)

Efficacy and safety of regorafenib versus dinutuximab with chemotherapy in Chinese children with neuroblastoma
by: Kun Dong, et al.
Published: (2019-02-01)

Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction
by: Margaret Cupit-Link, et al.
Published: (2023-09-01)

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
by: Filiz Cicek, et al.
Published: (2020-12-01)

Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model
by: Kimberly J. Ornell, et al.
Published: (2020-04-01)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
by: Paula Martínez-Sanz, et al.
Published: (2021-08-01)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
by: Nikolai Siebert, et al.
Published: (2023-06-01)

Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials
by: Hunter C. Jonus, et al.
Published: (2022-12-01)

Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse
by: Tim Flaadt, et al.
Published: (2023-09-01)

Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model
by: Renske J. E. van den Bijgaart, et al.
Published: (2020-01-01)

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
by: Keyel ME, et al.
Published: (2018-12-01)

Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis
by: Michelle L. Tas, et al.
Published: (2021-09-01)

Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments
by: Leah Klingel, et al.
Published: (2022-11-01)

Anxiolytic and hypnotic effects of Cocculus laurifolius leaf extract in mice
by: Sidra Maqbool, et al.
Published: (2019-02-01)

Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients
by: Stefano Mastrangelo, et al.
Published: (2021-11-01)

Verification of genetic differences and immune cell infiltration subtypes in the neuroblastoma tumour microenvironment during immunotherapy
by: Bo Qian, et al.
Published: (2022-05-01)

Identification of a Glycosyltransferase Signature for Predicting Prognosis and Immune Microenvironment in Neuroblastoma
by: Yongliang Sha, et al.
Published: (2022-01-01)

Research Progress of Efficacy Biomarkers Related to Immune Checkpoint Inhibitors
by: YANG Wenwen, et al.
Published: (2022-05-01)

Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy
by: Robert D. Carlson, et al.
Published: (2020-04-01)

Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
by: Jaume Mora, et al.
Published: (2021-03-01)

Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma
by: Fiorella Iglesias Cardenas, et al.
Published: (2021-12-01)

Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors
by: Hannah Schindler, et al.
Published: (2022-10-01)

The BET Protein Inhibitor JQ1 Decreases Hypoxia and Improves the Therapeutic Benefit of Anti-PD-1 in a High-Risk Neuroblastoma Mouse Model
by: Delphine Sauvage, et al.
Published: (2022-09-01)

Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients
by: Shayista Akbar, et al.
Published: (2023-01-01)

Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?
by: Anders Valind, et al.
Published: (2021-12-01)

Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report
by: Jaume Mora, et al.
Published: (2023-04-01)